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This editorial celebrates the launch of BMC Pharmacology and Toxicology within the BMC series of journals published
by BioMed Central. The scope of the journal is interdisciplinary encompassing toxicology, experimental and clinical
pharmacology including clinical trials. In this editorial we discuss the origins of this new journal and the ethos and
policies under which it will operate.Aims and scope
This month, our two pharmacologically-based titles
within the BMC series, BMC Pharmacology and BMC
Clinical Pharmacology, join forces under the new title
BMC Pharmacology and Toxicology. The scope of the
combined journal is broad, retaining the full scopes of
the original titles while also expanding to explicitly in-
clude the field of toxicology. The decision to merge the
journals was taken in response to feedback received from
key opinion leaders in the field and in consultation with
our Editorial Boards. The vast majority were in favour of a
wide-ranging journal, offering researchers the opportunity
to submit to and browse a general journal with a wider
audience than either of its component parts. A selection
of the feedback we received is given below.
“I think the merger is an excellent idea, especially since
the borders between pharmacology, clinical
pharmacology and toxicology can be rather ‘blurry’ and
because of clinical and translational sciences being a
major effort in the US and elsewhere”
Paul Insel, University of California, San Diego, USA
“The policy of launching the new BMC Pharmacology
and Toxicology journal is a far-sighted and modern
view and certainly the adjourned scopes and the new
sections are more appealing since they cover more
adequately the inter-related fields of Pharmacology and
Toxicology”
Giorgio Palu, Universtiy of Padua, Italy* Correspondence: elizabeth.moylan@biomedcentral.com
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reproduction in any medium, provided the or“Launching the merged journal is an excellent
opportunity to publish cutting-edge research on the
border of pharmacology and toxicology, which is
essential for modern drug discovery”
Maria Miteva, Inserm - University Paris Diderot,
France
“This merger would allow different readers, in terms of
cultural background and scientific interest, to get new
knowledge and expand their vision of science”
Maurizio Memo, University of Brescia Medical School,
Italy
The merger not only reflects the growing cross-
disciplinary nature of the field in this era of translational
medicine, but also to paraphrase Gregory Petsko, recog-
nises that “sometimes bigger is better, less is more, espe-
cially in an age where we need to think and read as
broadly as we can” [1]. We hope that the merger of
BMC Pharmacology and BMC Clinical Pharmacology
will facilitate connections across pre-clinical and clinical
research and that the communities which supported the
individual journals for the last 10 years will also support
this new venture. We welcome submissions which span
the fields of experimental and clinical pharmacology;
toxicology; drug design, discovery and delivery, and
computational, in silico and modelling studies.
BMC Pharmacology and Toxicology will maintain the
ethos of its predecessors and the rest of the BMC series
journals, and continue to publish work deemed by peer
reviewers to be a coherent and sound addition to scien-
tific knowledge. There will be less emphasis on interest
levels, provided that the research constitutes a usefulLtd. This is an Open Access article distributed under the terms of the Creative
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main open access and be freely accessible from the new
journal platform.
As with other journals in the BMC series, BMC
Pharmacology and Toxicology has an international Editorial
Board which retains many of the previous members of
BMC Pharmacology and BMC Clinical Pharmacology with
additional new faces. The journal is divided into a number
of subject-specific sections under the stewardship of aca-
demic Section Editors, who will be supported by academic
Associate Editors and Editorial Advisors as well as in-house
Editors. Dividing the journal into sections not only allows
authors to submit to a specific section but allows readers to
browse articles in a given section of interest to them and in
their field [3]. As an online journal we also make use of
article level metrics to indicate the most relevant and im-
portant publications to our readers [4] not least because
research published open access has the potential to reach a
much wider range of readers than a subscription-based
journal [5]. Publishing electronically also makes full use of
digital technologies and permits the inclusion of large data-
sets and links to animations and video clips.
Openness
BMC Pharmacology and Toxicology will operate an
open-peer review policy as is currently the case on all
medical titles within the BMC series [6]. There are two
levels to this “openness”. The first is that authors will
see the reviewers' names; the second is that the reading
public will also see who reviewed the article and how
the authors responded, if the article is published. This
will be available as part of the pre-publication history of
the published article.
Research into the effect of open peer review suggests
numerous benefits, the most important of which are ac-
countability, fairness, and giving credit to reviewers for
their efforts [7-9]. However, we recognise that there are
negatives also. Some (junior) reviewers may feel uncom-
fortable signing a critical report, especially when recom-
mending rejection [10]. The reluctance to open review
also means that more potential peer reviewers have to
be invited to review a manuscript openly than under a
peer review system which is closed Parkin EC et al. un-
published observations, [10-12]. However, given the
unique situation created by merging BMC Pharmacology
(with closed peer review) and BMC Clinical Pharmacol-
ogy (with open peer review) we have opted to make the
peer review process open and we will report on our find-
ings in the next two years. We believe that for a journal
publishing research frequently sponsored by pharma-
ceutical companies the potential benefits to openness
outweigh the negatives. By making peer review completely
transparent, we aim to reduce the competing interests that
can occur.BMC Pharmacology and Toxicology also supports ini-
tatives to promote open data sharing [13,14]. Our pub-
lisher, BioMedCentral, offers an annual Open Data
Award to recognize researchers who have published in
BioMed Central journals and have demonstrated leader-
ship in the sharing, standardization, publication, or re-
use of biomedical research data [15]. This is particularly
relevant given recent calls for policy reform of the US
Food and Drug Administration with respect to data
sharing on abandoned drugs which has the potential to
make the search for effective drugs more efficient [16].
Looking ahead
To launch BMC Pharmacology and Toxicology, we are
publishing the first in an occasional series of special re-
view articles. Our first review by Terry Kenakin focuses
on the potential for selective pharmacological therapies
based on the discovery that not all agonists uniformly
activate signalling pathways resulting in biased signalling
[17]. In the coming months, we will also be publishing a
series of interviews with our Section Editors in which
they discuss some of the topics of particular interest
within their subject-specific sections. In the first of these,
Phil Biggin gives his personal view on the key issues in
computational, in silico and modelling studies [18].
While the focus of the journal is to publish original
sound research, we also welcome commentaries and
correspondence that explore the expanding boundaries
of this field and suggest new opportunities for collabor-
ation between each discipline. The launch of BMC
Pharmacology and Toxicology marks the start of the next
phase of growth for journal. We do hope you will take
the time to visit the website and consider us for your
future submissions.
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